9.41
price up icon1.18%   0.11
pre-market  プレマーケット:  9.40   -0.010   -0.11%
loading
前日終値:
$9.30
開ける:
$9.31
24時間の取引高:
201.36K
Relative Volume:
0.21
時価総額:
$212.21M
収益:
$146.07M
当期純損益:
$-196.04M
株価収益率:
-0.5662
EPS:
-16.621
ネットキャッシュフロー:
$-75.37M
1週間 パフォーマンス:
+9.42%
1か月 パフォーマンス:
+59.76%
6か月 パフォーマンス:
+75.56%
1年 パフォーマンス:
+32.72%
1日の値動き範囲:
Value
$9.215
$9.52
1週間の範囲:
Value
$8.11
$9.55
52週間の値動き範囲:
Value
$3.6503
$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1106)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
228
Name
Twitter
@Karyopharm
Name
次回の収益日
2026-05-11
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, ALNY, ONC

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KPTI icon
KPTI
Karyopharm Therapeutics Inc
9.41 212.21M 146.07M -196.04M -75.37M -16.62
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
424.36 107.87B 12.32B 4.34B 3.19B 16.86
REGN icon
REGN
Regeneron Pharmaceuticals Inc
702.27 73.63B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
794.70 49.42B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
301.11 40.20B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
297.49 33.06B 5.36B 287.73M 924.18M 2.5229

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-10 開始されました Rodman & Renshaw Buy
2026-02-05 開始されました Cantor Fitzgerald Overweight
2025-10-13 アップグレード H.C. Wainwright Neutral → Buy
2025-07-16 ダウングレード H.C. Wainwright Buy → Neutral
2025-07-11 再開されました H.C. Wainwright Buy
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
May 04, 2026

Karyopharm (NASDAQ: KPTI) registers resale of 8.843M shares from private placement - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Karyopharm Therapeutics: Selling stockholder may resell up to 8,843,036 shares of Karyopharm common stockSEC filing - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

Karyopharm Therapeutics: Selling Stockholder May Resell Up To 8,843,036 Shares Of Karyopharm Common StockSEC Filing - TradingView

May 04, 2026
pulisher
May 04, 2026

Karyopharm Therapeutics may offer up to $400 million in securitiesSEC filing - marketscreener.com

May 04, 2026
pulisher
May 04, 2026

Karyopharm Therapeutics (NASDAQ: KPTI) files $400M shelf, $100M ATM with Jefferies - Stock Titan

May 04, 2026
pulisher
May 04, 2026

Karyopharm (KPTI) Q1 2025 Earnings Transcript - AOL.com

May 04, 2026
pulisher
Apr 29, 2026

Karyopharm to seek label expansion for Xpovio in myelofibrosis after late-stage trial win - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

KPTI stock down on mixed phase III myelofibrosis combo study data - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

KPTI stock slumps pre-market even as Karyopharm’s myelofibrosis treatment meets primary endpoint — retail doubtful about FDA approval - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

Karyopharm Therapeutics (KPTI) price target increased by 13.33% to 13.87 - MSN

Apr 29, 2026
pulisher
Apr 28, 2026

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 28, 2026
pulisher
Apr 27, 2026

Piper Sandler Reiterates Overweight Rating for Karyopharm Therapeutics (NASDAQ:KPTI) - MarketBeat

Apr 27, 2026
pulisher
Apr 27, 2026

KPTI Upgraded by Piper Sandler -- Price Target Raised to $16.00 - GuruFocus

Apr 27, 2026
pulisher
Apr 27, 2026

Piper Sandler Maintains Karyopharm Therapeutics(KPTI.US) With Buy Rating, Raises Target Price to $16 - Moomoo

Apr 27, 2026
pulisher
Apr 26, 2026

Karyopharm Therapeutics jumps 18%, raises $30M privately - MSN

Apr 26, 2026
pulisher
Apr 24, 2026

Karyopharm Therapeutics (KPTI) price target decreased by 22.08% to 12.24 - MSN

Apr 24, 2026
pulisher
Apr 22, 2026

Is Karyopharm Therapeutics (KPTI) stock considered a safe play | Q4 2025: Below ExpectationsPricing Power - Cổng thông tin điện tử tỉnh Lào Cai

Apr 22, 2026
pulisher
Apr 22, 2026

Karyopharm (KPTI) CMO logs pre-planned tax-related sale of 449 shares - Stock Titan

Apr 22, 2026
pulisher
Apr 21, 2026

Karyopharm’s myelofibrosis trial selected for ASCO presentation By Investing.com - Investing.com Australia

Apr 21, 2026
pulisher
Apr 21, 2026

Karyopharm’s myelofibrosis trial selected for ASCO presentation - Investing.com

Apr 21, 2026
pulisher
Apr 21, 2026

Karyopharm's Phase 3 SENTRY Trial in Myelofibrosis Selected for Late-Breaking Oral Presentation at ASCO 2026 Annual Meeting - Karyopharm

Apr 21, 2026
pulisher
Apr 21, 2026

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50 Day Moving AverageWhat's Next? - MarketBeat

Apr 21, 2026
pulisher
Apr 20, 2026

Is Karyopharm Therapeutics (KPTI) stock a smart investment today (Bullish Sentiment) 2026-04-20Risk Reward Ratio - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026
pulisher
Apr 17, 2026

RBC Flags Seasonal Pressures Impacting Karyopharm Therapeutics Inc. (KPTI) Short-Term Performance - Insider Monkey

Apr 17, 2026
pulisher
Apr 16, 2026

KPTI SEC FilingsKaryopharm Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 16, 2026
pulisher
Apr 16, 2026

Karyopharm Therapeutics : Corporate Presentation - marketscreener.com

Apr 16, 2026

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$28.32
price down icon 0.14%
$50.44
price up icon 0.48%
$95.50
price down icon 3.88%
$139.44
price down icon 0.41%
$147.21
price down icon 0.47%
ONC ONC
$297.49
price up icon 0.12%
大文字化:     |  ボリューム (24 時間):